FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146458227> ?p ?o ?g. }

• W2146458227 endingPage "507" @default.
• W2146458227 startingPage "487" @default.
• W2146458227 abstract "Despite potential benefits, primary care clinicians may avoid using antimuscarinics in men with overactive bladder (OAB) symptoms because of safety concerns. To review the efficacy and safety of antimuscarinics, alone or in combination with an α-blocker, for the treatment of men with OAB symptoms, we conducted a systematic review of articles published before 22 July 2010, using PubMed. Data from 12-week, randomised, double-blind, placebo-controlled trials of tolterodine extended release (ER), oxybutynin and solifenacin show that combined antimuscarinic+α-blocker treatment is generally more effective than monotherapy or placebo in men with OAB symptoms. The efficacy and safety of tolterodine ER+α-blocker treatment was not affected by prostate size or prostate-specific antigen (PSA) level. In men meeting entry criteria for OAB and benign prostatic obstruction trials, tolterodine ER alone was effective selectively in men with prostate size or PSA level below study medians. Incidence of acute urinary retention (AUR) in men receiving antimuscarinics with or without an α-blocker was ≤3% in all of these trials; changes in postvoid residual volume and maximum flow rate did not appear clinically meaningful. Post hoc analyses from double-blind, placebo-controlled trials and prospective studies of fesoterodine, oxybutynin, propiverine, solifenacin and tolterodine also suggest that antimuscarinics are generally safe and efficacious in men. A retrospective database study found that risk of AUR in men was the highest in the first month of treatment and decreased considerably thereafter. Antimuscarinics, alone or with an α-blocker, appear to be efficacious and safe in many men with predominant OAB symptoms or persistent OAB symptoms despite α-blocker or 5-α-reductase inhibitor treatment. However, antimuscarinics are not approved for the treatment of benign prostatic hyperplasia. Monitoring men for AUR is recommended, especially those at increased risk, and particularly within 30 days after starting antimuscarinic treatment." @default.
• W2146458227 created "2016-06-24" @default.
• W2146458227 creator A5001479798 @default.
• W2146458227 creator A5038940693 @default.
• W2146458227 creator A5049019006 @default.
• W2146458227 creator A5080266362 @default.
• W2146458227 creator A5081214299 @default.
• W2146458227 creator A5085416965 @default.
• W2146458227 date "2011-01-07" @default.
• W2146458227 modified "2023-10-14" @default.
• W2146458227 title "Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review" @default.
• W2146458227 cites W1514921595 @default.
• W2146458227 cites W1567909777 @default.
• W2146458227 cites W1568619399 @default.
• W2146458227 cites W1585489386 @default.
• W2146458227 cites W1962053352 @default.
• W2146458227 cites W1967347194 @default.
• W2146458227 cites W1968860914 @default.
• W2146458227 cites W1968865622 @default.
• W2146458227 cites W1969218478 @default.
• W2146458227 cites W1972275101 @default.
• W2146458227 cites W1979876046 @default.
• W2146458227 cites W1983094092 @default.
• W2146458227 cites W1987858646 @default.
• W2146458227 cites W1992243709 @default.
• W2146458227 cites W2007668739 @default.
• W2146458227 cites W2012932483 @default.
• W2146458227 cites W2014461997 @default.
• W2146458227 cites W2018142772 @default.
• W2146458227 cites W2020443535 @default.
• W2146458227 cites W2020680714 @default.
• W2146458227 cites W2022422644 @default.
• W2146458227 cites W2022805390 @default.
• W2146458227 cites W2024922462 @default.
• W2146458227 cites W2038679265 @default.
• W2146458227 cites W2045828646 @default.
• W2146458227 cites W2051464421 @default.
• W2146458227 cites W2055614074 @default.
• W2146458227 cites W2060253131 @default.
• W2146458227 cites W2061642216 @default.
• W2146458227 cites W2065814656 @default.
• W2146458227 cites W2067889220 @default.
• W2146458227 cites W2068543068 @default.
• W2146458227 cites W2070418921 @default.
• W2146458227 cites W2073337601 @default.
• W2146458227 cites W2078997630 @default.
• W2146458227 cites W2082982324 @default.
• W2146458227 cites W2088552272 @default.
• W2146458227 cites W2089437227 @default.
• W2146458227 cites W2089534404 @default.
• W2146458227 cites W2093958389 @default.
• W2146458227 cites W2118950858 @default.
• W2146458227 cites W2121759271 @default.
• W2146458227 cites W2127743572 @default.
• W2146458227 cites W2131173377 @default.
• W2146458227 cites W2134121470 @default.
• W2146458227 cites W2134928141 @default.
• W2146458227 cites W2136535014 @default.
• W2146458227 cites W2164856644 @default.
• W2146458227 cites W2168942726 @default.
• W2146458227 cites W2314251966 @default.
• W2146458227 cites W4249655375 @default.
• W2146458227 cites W4249807744 @default.
• W2146458227 cites W4294545090 @default.
• W2146458227 doi "https://doi.org/10.1111/j.1742-1241.2010.02611.x" @default.
• W2146458227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21210910" @default.
• W2146458227 hasPublicationYear "2011" @default.
• W2146458227 type Work @default.
• W2146458227 sameAs 2146458227 @default.
• W2146458227 citedByCount "72" @default.
• W2146458227 countsByYear W21464582272012 @default.
• W2146458227 countsByYear W21464582272013 @default.
• W2146458227 countsByYear W21464582272014 @default.
• W2146458227 countsByYear W21464582272015 @default.
• W2146458227 countsByYear W21464582272016 @default.
• W2146458227 countsByYear W21464582272017 @default.
• W2146458227 countsByYear W21464582272018 @default.
• W2146458227 countsByYear W21464582272020 @default.
• W2146458227 countsByYear W21464582272021 @default.
• W2146458227 crossrefType "journal-article" @default.
• W2146458227 hasAuthorship W2146458227A5001479798 @default.
• W2146458227 hasAuthorship W2146458227A5038940693 @default.
• W2146458227 hasAuthorship W2146458227A5049019006 @default.
• W2146458227 hasAuthorship W2146458227A5080266362 @default.
• W2146458227 hasAuthorship W2146458227A5081214299 @default.
• W2146458227 hasAuthorship W2146458227A5085416965 @default.
• W2146458227 hasBestOaLocation W21464582271 @default.
• W2146458227 hasConcept C121608353 @default.
• W2146458227 hasConcept C126322002 @default.
• W2146458227 hasConcept C126894567 @default.
• W2146458227 hasConcept C142724271 @default.
• W2146458227 hasConcept C204787440 @default.
• W2146458227 hasConcept C27081682 @default.
• W2146458227 hasConcept C2776235491 @default.
• W2146458227 hasConcept C2776547966 @default.
• W2146458227 hasConcept C2777844464 @default.
• W2146458227 hasConcept C2778941218 @default.
• W2146458227 hasConcept C2779478474 @default.

• next